Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
SafeMoon CEO reapplies to dismiss lawsuit on the grounds of the U.S. Department of Justice dissolving its cryptocurrency department

SafeMoon CEO reapplies to dismiss lawsuit on the grounds of the U.S. Department of Justice dissolving its cryptocurrency department

Bitget2025/04/10 10:10

According to Cointelegraph, Braden John Karony, CEO of the crypto project SafeMoon, recently cited the latest policy from the U.S. Department of Justice in an attempt to overturn allegations of securities fraud against him. His defense attorney Nicholas Smith stated in a document submitted to the New York Federal Court on April 9 that according to new regulations from the Department of Justice on April 7, prosecutors should avoid using securities law provisions when dealing with cryptocurrency cases - unless parties voluntarily request asset recognition and Karony "explicitly expressed no intention to self-certify".

In November 2023, both the Department of Justice and SEC brought charges against Karony and other senior executives at SafeMoon for securities violations, wire fraud and money laundering. This letter is Karony's latest attempt to have his case dismissed. In February he requested a delay in his trial originally scheduled for March 31st citing potential impacts from President Trump's proposed cryptocurrency policies on his case. Earlier this year in February news broke that Thomas Smith, Chief Technology Officer at SafeMoon admitted involvement in a $200 million cryptocurrency fraud case.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

From $617 to $350: CVS Sets "Break-Even Price" for Weight-Loss Drugs, Says Pharmaceutical Companies Can Still Profit

An analysis of insurance claims data found that if GLP-1 drugs used for weight loss and diabetes are priced below $350 per month, payers—such as employers and plan sponsors—would achieve net savings due to a decrease in related healthcare service utilization.

智通财经•2026/11/15 04:01
From $617 to $350: CVS Sets "Break-Even Price" for Weight-Loss Drugs, Says Pharmaceutical Companies Can Still Profit

UNI falls below $5

金色财经•2026/11/15 03:37
UNI falls below $5